1037 related articles for article (PubMed ID: 29898853)
1. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Bansilal S; Bhatt DL; Leiter LA; McGuire DK; Wilding JP; Gause-Nilsson IA; Langkilde AM; Johansson PA; Sabatine MS
Am Heart J; 2018 Jun; 200():83-89. PubMed ID: 29898853
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Zelniker TA; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS;
N Engl J Med; 2019 Jan; 380(4):347-357. PubMed ID: 30415602
[TBL] [Abstract][Full Text] [Related]
4. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Furtado RHM; Raz I; Goodrich EL; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Aylward P; Dalby AJ; Dellborg M; Dimulescu D; Nicolau JC; Oude Ophuis AJM; Cahn A; Mosenzon O; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2022 May; 145(21):1581-1591. PubMed ID: 35510542
[TBL] [Abstract][Full Text] [Related]
6. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
Bonaca MP; Wiviott SD; Zelniker TA; Mosenzon O; Bhatt DL; Leiter LA; McGuire DK; Goodrich EL; De Mendonca Furtado RH; Wilding JPH; Cahn A; Gause-Nilsson IAM; Johanson P; Fredriksson M; Johansson PA; Langkilde AM; Raz I; Sabatine MS
Circulation; 2020 Aug; 142(8):734-747. PubMed ID: 32795086
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin: A Review in Type 2 Diabetes.
Dhillon S
Drugs; 2019 Jul; 79(10):1135-1146. PubMed ID: 31236801
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
O'Donoghue ML; Kato ET; Mosenzon O; Murphy SA; Cahn A; Herrera M; Tankova T; Šmahelová A; Merlini P; Gause-Nilsson I; Langkilde AM; McGuire DK; Wilding JPH; Leiter LA; Bhatt DL; Raz I; Sabatine MS; Wiviott SD
Diabetologia; 2021 Jun; 64(6):1226-1234. PubMed ID: 33611623
[TBL] [Abstract][Full Text] [Related]
10. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
[TBL] [Abstract][Full Text] [Related]
11. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Norhammar A; Bodegård J; Nyström T; Thuresson M; Nathanson D; Eriksson JW
Diabetes Obes Metab; 2019 May; 21(5):1136-1145. PubMed ID: 30609272
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
14. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
15. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236
[TBL] [Abstract][Full Text] [Related]
16. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
[TBL] [Abstract][Full Text] [Related]
17. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
Oyama K; Raz I; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Park KS; Goudev A; Diaz R; Špinar J; Gause-Nilsson IAM; Mosenzon O; Sabatine MS; Wiviott SD
Eur Heart J; 2022 Aug; 43(31):2958-2967. PubMed ID: 34427295
[TBL] [Abstract][Full Text] [Related]
18. Current Role of Dapagliflozin in Clinical Practice.
Zargar AH; Trailokya AA; Ghag S; Pawar R; Aiwale A; Zalke A
J Assoc Physicians India; 2021 Sep; 69(9):11-12. PubMed ID: 34585897
[TBL] [Abstract][Full Text] [Related]
19. DECLARE-TIMI 58: Participants' baseline characteristics.
Raz I; Mosenzon O; Bonaca MP; Cahn A; Kato ET; Silverman MG; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson IAM; Langkilde AM; Johansson PA; Sabatine MS; Wiviott SD
Diabetes Obes Metab; 2018 May; 20(5):1102-1110. PubMed ID: 29322605
[TBL] [Abstract][Full Text] [Related]
20. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.
Zelniker TA; Wiviott SD; Mosenzon O; Goodrich EL; Jarolim P; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding J; Averkov O; Budaj A; Parkhomenko A; Ray KK; Gause-Nilsson I; Langkilde AM; Fredriksson M; Raz I; Sabatine MS; Morrow DA
JAMA Cardiol; 2023 May; 8(5):503-509. PubMed ID: 36857035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]